BR0007158A - Peptìdeos de ezrina reguladores / não dobráveis - Google Patents
Peptìdeos de ezrina reguladores / não dobráveisInfo
- Publication number
- BR0007158A BR0007158A BR0007158-7A BR0007158A BR0007158A BR 0007158 A BR0007158 A BR 0007158A BR 0007158 A BR0007158 A BR 0007158A BR 0007158 A BR0007158 A BR 0007158A
- Authority
- BR
- Brazil
- Prior art keywords
- ezrine
- hepreceptor
- amino acid
- human
- peptides
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000001105 regulatory effect Effects 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 239000012528 membrane Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101000854648 Homo sapiens Ezrin Proteins 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Patente de Invenção: <B>"PEPTìDEOS DE EZRINA REGULADORES / NãO-DOBRáVEIS"<D> Essa invenção descreve novas moléculas carregadas, que se ligam de maneira específica ao Hepreceptor, um sítio regulador que o inventor descobriu na ezrina humana. A invenção consiste no fato de que, quando os peptídeos ou outras moléculas carregadas se ligam ao Hepreceptor, respostas imunes medicamente úteis são induzidas. Essas moléculas carregadas podem ser administradas oralmente e por outras rotas para o tratamento de várias doenças infecciosas e de câncer. O inventor determinou que o Hepreceptor (ezrina humana 308 a 373) compreende dois domínios alfa-helicoidais adjacentes, que estão dobrados em conjunto em uma região de dobradiça (M339 a M340) e estabilizados por cargas de cadeias laterais complementares da seq³ência de aminoácidos primária, na conformação citoplásmica solúvel de ezrina. O inventor determinou que, na conformação associada à membrana não dobrada da ezrina, o Hepreceptor é empurrado através da membrana da célula e é exposto na superfície externa da célula. O Domínio A de Hepreceptor (números de aminoácidos 308 a 339 de ezrina humana) compreende a seq³ência de 32 aminoácidos seguinte: SEQ ID 1 A R E E K H Q K Q L E R Q Q L E T E K K R R E T V E R E K E Q M. O Domínio B de Hepreceptor (números de aminoácidos 340 a 373 de ezrina humana) compreende a seq³ência de 34 aminoácidos seguinte (a tirosina 353 [Y] pode estar fosforilada para formar fosfotirosina [Yp] na conformação associada à membrana da ezrina): SEQ ID 2 M R E K E E L M L R L Q D Y(p) E E K T K K A E R E L S E Q I Q R A L Q.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9921881A GB2354241A (en) | 1999-09-17 | 1999-09-17 | Regulatory/unfolding peptides of ezrin |
| PCT/GB2000/003566 WO2001025275A1 (en) | 1999-09-17 | 2000-09-15 | Regulatory/unfolding peptides of ezrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0007158A true BR0007158A (pt) | 2001-07-31 |
Family
ID=10861009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0007158-7A BR0007158A (pt) | 1999-09-17 | 2000-09-15 | Peptìdeos de ezrina reguladores / não dobráveis |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6849596B1 (pt) |
| EP (2) | EP1131348B1 (pt) |
| JP (1) | JP2003511389A (pt) |
| KR (1) | KR20010101017A (pt) |
| CN (1) | CN100387619C (pt) |
| AT (1) | ATE356144T1 (pt) |
| AU (1) | AU770208B2 (pt) |
| BR (1) | BR0007158A (pt) |
| CA (1) | CA2348780A1 (pt) |
| CY (1) | CY1106644T1 (pt) |
| CZ (1) | CZ20011689A3 (pt) |
| DE (1) | DE60033783T2 (pt) |
| DK (1) | DK1131348T3 (pt) |
| ES (1) | ES2283317T3 (pt) |
| GB (1) | GB2354241A (pt) |
| HU (1) | HUP0104254A3 (pt) |
| NO (1) | NO20012417L (pt) |
| NZ (1) | NZ511747A (pt) |
| PL (1) | PL348635A1 (pt) |
| PT (1) | PT1131348E (pt) |
| RU (1) | RU2215005C2 (pt) |
| WO (1) | WO2001025275A1 (pt) |
| ZA (1) | ZA200103938B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0301879D0 (en) * | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
| WO2007060440A2 (en) * | 2005-11-23 | 2007-05-31 | Regent Research L.L.P. | The use of peptides in anti-ulcer therapy |
| CN100455665C (zh) * | 2006-11-21 | 2009-01-28 | 汕头大学医学院 | 人食管癌细胞ezrin基因上游转录调控元件 |
| WO2009103312A1 (en) * | 2008-02-19 | 2009-08-27 | Ludwig-Maximilians-Universität | Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases |
| RU2580629C1 (ru) * | 2015-05-15 | 2016-04-10 | Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ прогнозирования рецептивности эндометрия на основании оценки экспрессии и внутриклеточной локализации эзрина в эндометрии женщин с бесплодием и повторными неудачами программы эко |
| MD3191504T2 (ro) * | 2015-06-01 | 2018-04-30 | Nearmedic International Ltd | Peptide derivate din ezrin și compozițiile farmaceutice ale acestora |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2290293A (en) * | 1994-06-08 | 1995-12-20 | Rupert Donald Holms | Preparation which inhibits the autoimmune response in HIV, or SLE, patients |
| WO1997012975A1 (en) | 1995-10-02 | 1997-04-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | An epithelial protein and dna thereof for use in early cancer detection |
| US6399584B1 (en) * | 1998-03-18 | 2002-06-04 | Institute Curie | Pharmaceutical composition containing ezrin mutated on tyrosine 353 |
-
1999
- 1999-09-17 GB GB9921881A patent/GB2354241A/en not_active Withdrawn
-
2000
- 2000-09-15 CZ CZ20011689A patent/CZ20011689A3/cs unknown
- 2000-09-15 HU HU0104254A patent/HUP0104254A3/hu unknown
- 2000-09-15 CN CNB008022844A patent/CN100387619C/zh not_active Expired - Fee Related
- 2000-09-15 US US09/856,070 patent/US6849596B1/en not_active Expired - Fee Related
- 2000-09-15 AT AT00962685T patent/ATE356144T1/de not_active IP Right Cessation
- 2000-09-15 KR KR1020017006187A patent/KR20010101017A/ko not_active Application Discontinuation
- 2000-09-15 JP JP2001528215A patent/JP2003511389A/ja not_active Withdrawn
- 2000-09-15 EP EP00962685A patent/EP1131348B1/en not_active Expired - Lifetime
- 2000-09-15 DE DE60033783T patent/DE60033783T2/de not_active Expired - Fee Related
- 2000-09-15 RU RU2001113277/04A patent/RU2215005C2/ru not_active IP Right Cessation
- 2000-09-15 PL PL00348635A patent/PL348635A1/xx unknown
- 2000-09-15 DK DK00962685T patent/DK1131348T3/da active
- 2000-09-15 ES ES00962685T patent/ES2283317T3/es not_active Expired - Lifetime
- 2000-09-15 CA CA002348780A patent/CA2348780A1/en not_active Abandoned
- 2000-09-15 AU AU74333/00A patent/AU770208B2/en not_active Ceased
- 2000-09-15 WO PCT/GB2000/003566 patent/WO2001025275A1/en active IP Right Grant
- 2000-09-15 BR BR0007158-7A patent/BR0007158A/pt not_active IP Right Cessation
- 2000-09-15 NZ NZ511747A patent/NZ511747A/xx unknown
- 2000-09-15 EP EP06009089A patent/EP1760090A1/en not_active Withdrawn
- 2000-09-15 PT PT00962685T patent/PT1131348E/pt unknown
-
2001
- 2001-05-15 ZA ZA200103938A patent/ZA200103938B/en unknown
- 2001-05-16 NO NO20012417A patent/NO20012417L/no not_active Application Discontinuation
-
2007
- 2007-06-06 CY CY20071100749T patent/CY1106644T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60033783D1 (de) | 2007-04-19 |
| EP1131348B1 (en) | 2007-03-07 |
| DK1131348T3 (da) | 2007-07-09 |
| PT1131348E (pt) | 2007-11-19 |
| AU7433300A (en) | 2001-05-10 |
| NZ511747A (en) | 2004-03-26 |
| GB9921881D0 (en) | 1999-11-17 |
| ES2283317T3 (es) | 2007-11-01 |
| ATE356144T1 (de) | 2007-03-15 |
| WO2001025275A9 (en) | 2002-07-25 |
| CN1327450A (zh) | 2001-12-19 |
| NO20012417L (no) | 2001-07-16 |
| KR20010101017A (ko) | 2001-11-14 |
| EP1131348A1 (en) | 2001-09-12 |
| PL348635A1 (en) | 2002-06-03 |
| WO2001025275A1 (en) | 2001-04-12 |
| DE60033783T2 (de) | 2007-11-15 |
| CA2348780A1 (en) | 2001-04-12 |
| HUP0104254A3 (en) | 2002-05-28 |
| GB2354241A (en) | 2001-03-21 |
| JP2003511389A (ja) | 2003-03-25 |
| US6849596B1 (en) | 2005-02-01 |
| CZ20011689A3 (cs) | 2001-12-12 |
| AU770208B2 (en) | 2004-02-19 |
| RU2215005C2 (ru) | 2003-10-27 |
| HUP0104254A2 (hu) | 2002-04-29 |
| NO20012417D0 (no) | 2001-05-16 |
| EP1760090A1 (en) | 2007-03-07 |
| CN100387619C (zh) | 2008-05-14 |
| CY1106644T1 (el) | 2012-01-25 |
| ZA200103938B (en) | 2002-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eisele et al. | In vitro folding and oligomerization of a membrane protein. Transition of bacterial porin from random coil to native conformation. | |
| Arakawa et al. | Protection of bovine serum albumin from aggregation by Tween 80 | |
| Wieslander et al. | Physical and immunochemical studies of the globular domain of type IV collagen. Cryptic properties of the Goodpasture antigen. | |
| Huang et al. | Refolding of an integral membrane protein. Denaturation, renaturation, and reconstitution of intact bacteriorhodopsin and two proteolytic fragments. | |
| Arai et al. | ACE inhibitors and pneumonia in elderly people | |
| AU677603B2 (en) | Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues | |
| JPS61126099A (ja) | 両極性ペプチド | |
| ES2036983T3 (es) | Antigenos reconocidos por anticuerpos de la poliartritis reumatoide, su preparacion y sus aplicaciones. | |
| BR0007158A (pt) | Peptìdeos de ezrina reguladores / não dobráveis | |
| JPH0137398B2 (pt) | ||
| Sorgente et al. | The isolation, purification and partial characterization of proteinase inhibitors from bovine cartilage and aorta | |
| Huszar et al. | ε-N-methyl lysine in myosin | |
| KR20110063731A (ko) | 펩티딜아르기닌 디이미나아제(ｐａｄ) 억제제 | |
| García-Linares et al. | The metamorphic transformation of a water-soluble monomeric protein into an oligomeric transmembrane pore | |
| Augusteyn | Dissociation is not required for α-crystallin's chaperone function | |
| Goto et al. | Effects of ammonium sulfate on the unfolding and refolding of the variable and constant fragments of an immunoglobulin light chain | |
| BR0309421A (pt) | Composições de proteìna associada com corpo oleoso e métodos de uso destas para reduzir o risco de doença cardiovascular | |
| Alvares et al. | Effects of a polar amino acid substitution on helix formation and aggregate size along the detergent-induced peptide folding pathway | |
| BR9914929A (pt) | Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas | |
| BR0016419A (pt) | Método para o aumento das respostas de imunização com relação a vacina do vìrus do herpes simplex | |
| DK2670420T3 (en) | Antiviral agent containing recombinant mistletoe lectins | |
| Cardin et al. | Structural organization of apolipoprotein B-100 of human plasma low density lipoproteins. Comparison to B-48 of chylomicrons and very low density lipoproteins. | |
| AU731317B2 (en) | New BPC peptide salts with organo-protective activity, the process for their preparation and their use in therapy | |
| BR0309966A (pt) | Muteìnas de fator de crescimento placentário tipo 1, método de preparação e seus usos | |
| Bay et al. | Spectroscopic analysis of small multidrug resistance protein EmrE in the presence of various quaternary cation compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A , 10A E 11A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011. |